Keros Therapeutics, Inc. (KROS)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 80M 160M 240M Q1 '19: 2.5M Q2 '19: 2.5M Q3 '19: 2.5M Q4 '19: 2.5M Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q2 '21: 100K Q3 '21: 0 Q4 '21: 20M Q1 '22: 0 Q2 '22: 0 Q3 '22: 0 Q4 '22: 0 Q1 '23: 0 Q2 '23: 0 Q3 '23: 8K Q4 '23: 143K Q1 '24: 83K Q2 '24: 37K Q3 '24: 388K Q4 '24: 3M Q1 '25: 211.2M Q2 '25: 18.2M Q3 '25: 14.3M Q4 '25: 385K Q1 '26: 367K Q2 '26: 0 Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-60M 0 60M 120M 180M Q1 '19: -2.9M Q2 '19: -2.7M Q3 '19: -2.3M Q4 '19: -2.7M Q1 '20: -10.5M Q2 '20: -10.9M Q3 '20: -11.9M Q4 '20: -13.3M Q1 '21: -15.8M Q2 '21: -15.5M Q3 '21: -20.2M Q4 '21: -4.9M Q1 '22: -24.1M Q2 '22: -30.7M Q3 '22: -28M Q4 '22: -32M Q1 '23: -38.9M Q2 '23: -41.3M Q3 '23: -43.3M Q4 '23: -46.5M Q1 '24: -48.5M Q2 '24: -50.4M Q3 '24: -58.7M Q4 '24: -53.3M Q1 '25: 152M Q2 '25: -39.8M Q3 '25: -15.4M Q4 '25: -29.3M Q1 '26: -25.9M Q2 '26: -30.9M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-60M 0 60M 120M 180M Q1 '19: -3.2M Q2 '19: -2.9M Q3 '19: -3.5M Q4 '19: -2.8M Q1 '20: -11.9M Q2 '20: -10.8M Q3 '20: -12M Q4 '20: -10.7M Q1 '21: -15.9M Q2 '21: -15.6M Q3 '21: -20.3M Q4 '21: -6.9M Q1 '22: -24.2M Q2 '22: -27.3M Q3 '22: -23.5M Q4 '22: -29.7M Q1 '23: -35.8M Q2 '23: -37.5M Q3 '23: -39.4M Q4 '23: -40.2M Q1 '24: -43.1M Q2 '24: -45.3M Q3 '24: -53M Q4 '24: -46M Q1 '25: 148.5M Q2 '25: -30.7M Q3 '25: -7.3M Q4 '25: -23.5M Q1 '26: -23.7M Q2 '26: -28.7M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-60M 0 60M 120M 180M Q1 '19: -2.5M Q2 '19: -5M Q3 '19: -3M Q4 '19: -5.5M Q1 '20: -8.1M Q2 '20: -9.9M Q3 '20: -10.9M Q4 '20: -8M Q1 '21: -10.5M Q2 '21: -17.6M Q3 '21: -14.4M Q4 '21: -19.6M Q1 '22: -1.4M Q2 '22: -22.6M Q3 '22: -24.6M Q4 '22: -21.4M Q1 '23: -34.2M Q2 '23: -30.8M Q3 '23: -34M Q4 '23: -25.5M Q1 '24: -44.6M Q2 '24: -39.8M Q3 '24: -30.5M Q4 '24: -46M Q1 '25: 161.2M Q2 '25: -29.6M Q3 '25: 3.2M Q4 '25: -27.3M Q1 '26: -3.5M Q2 '26: -20.4M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Free Cash Flow Quarterly

-60M 0 60M 120M 180M Q1 '19: -2.5M Q2 '19: -5.2M Q3 '19: -3M Q4 '19: -5.5M Q1 '20: -8.3M Q2 '20: -10M Q3 '20: -10.9M Q4 '20: -8.1M Q1 '21: -10.7M Q2 '21: -18.1M Q3 '21: -14.6M Q4 '21: -19.7M Q1 '22: -1.6M Q2 '22: -23.2M Q3 '22: -24.8M Q4 '22: -21.8M Q1 '23: -35.3M Q2 '23: -31.1M Q3 '23: -34.5M Q4 '23: -26M Q1 '24: -45.5M Q2 '24: -40.1M Q3 '24: -30.9M Q4 '24: -46.3M Q1 '25: 160.6M Q2 '25: -30.3M Q3 '25: 3.1M Q4 '25: -27.4M Q1 '26: -3.6M Q2 '26: -20.6M Q2 '19 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '20: 17.6M Q3 '20: 20.2M Q1 '21: 23.2M Q2 '21: 23.3M Q3 '21: 23.4M Q1 '22: 24M Q2 '22: 24.1M Q3 '22: 25.5M Q1 '23: 28.4M Q2 '23: 29.6M Q3 '23: 29.7M Q1 '24: 35.7M Q2 '24: 36.1M Q3 '24: 37.6M Q1 '25: 41M Q2 '25: 40.6M Q3 '25: 40.6M Q1 '26: 19.6M Q2 '26: 19.8M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-10.50 -7.00 -3.50 0.00 3.50 7.00 10.50 Q4 '19: -6.08 Q1 '20: -9.58 Q2 '20: -8.76 Q3 '20: -7.65 Q4 '20: -6.61 Q1 '21: -2.18 Q2 '21: -2.23 Q3 '21: -2.50 Q4 '21: -2.52 Q1 '22: -2.85 Q2 '22: -3.31 Q3 '22: -3.36 Q4 '22: -4.16 Q1 '23: -4.41 Q2 '23: -4.55 Q3 '23: -4.96 Q4 '23: -5.20 Q1 '24: -5.15 Q2 '24: -5.13 Q3 '24: -5.21 Q4 '24: -4.99 Q1 '25: -0.16 Q2 '25: 0.33 Q3 '25: 1.56 Q4 '25: 2.30 Q1 '26: -2.53 Q2 '26: -3.22 Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.